AbCellera Biologics (NASDAQ:ABCL – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare AbCellera Biologics to similar companies based on the strength of its institutional ownership, valuation, dividends, earnings, analyst recommendations, risk and profitability.
Analyst Ratings
This is a summary of recent ratings and target prices for AbCellera Biologics and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbCellera Biologics | 1 | 1 | 7 | 2 | 2.91 |
| AbCellera Biologics Competitors | 9923 | 15313 | 45658 | 1602 | 2.54 |
AbCellera Biologics currently has a consensus target price of $16.20, suggesting a potential upside of 40.99%. As a group, “Biotechnology” companies have a potential upside of 126.42%. Given AbCellera Biologics’ rivals higher possible upside, analysts plainly believe AbCellera Biologics has less favorable growth aspects than its rivals.
Institutional and Insider Ownership
61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
AbCellera Biologics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, AbCellera Biologics’ rivals have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.
Profitability
This table compares AbCellera Biologics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbCellera Biologics | -218.54% | -15.35% | -10.84% |
| AbCellera Biologics Competitors | -12,224.09% | -202.33% | -31.23% |
Valuation & Earnings
This table compares AbCellera Biologics and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| AbCellera Biologics | $67.85 million | -$146.41 million | -23.94 |
| AbCellera Biologics Competitors | $738.96 million | $10.45 million | -18.81 |
AbCellera Biologics’ rivals have higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
AbCellera Biologics beats its rivals on 9 of the 13 factors compared.
About AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
